Intravitreal infliximab clearance in a rabbit model: Different sampling methods and assay techniques

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 11, 2009, Pages 5328-5335

  Giansanti, Fabrizio ^a   Ramazzotti, Matteo ^b   Giuntoli, Matteo ^a   Virgili, Gianni ^a   Vannozzi, Lorenzo ^a   Degl'Innocenti, Donatella ^b   Menchini, Ugo ^a  

^a Departments of Oto Neuro Ophthalmological Surgical Sciences   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOT HYBRIDIZATION; DRUG ADMINISTRATION ROUTE; DRUG CLEARANCE; DRUG DIFFUSION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; ENUCLEATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL RABBIT; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; VITREOUS BODY; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; INJECTIONS; MODELS, ANIMAL; RABBITS; SPECIMEN HANDLING; TUMOR NECROSIS FACTOR-ALPHA; VITREOUS BODY;

EID: 77958194250     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3569     Document Type: Article

References (36)

1. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104(4): 487-501.
2. Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004;23(6):617-637.
3. Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor alpha in clinical uveitis. Ophthalmic Res. 2001;33:251-255.
4. Okada AA, Sakai J, Usui M, Mizuguchi J. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm. 1998;6(2):111-120.
5. Limb GA, Chignell AH, Green W, LeRoy F, Dumonde DC. Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol. 1996;80(2):168-173.
6. Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A. TNF-alpha level in the vitreous body: increase in neovascular eye diseases and proliferative diabetic retinopathy. Med Klin (Munich). 1995;90(3):134-137.
7. Armstrong D, Augustin AJ, Spengler R, et al. Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica. 1998;212(6):410-414.
8. Armstrong D, Ueda T, Ueda T, et al. Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor. Angiogenesis. 1998;2(1):93-104.
9. Kociok N, Radetzky S, Krohne TU, Gavranic C, Joussen AM. Pathological but not physiological retinal neovascularization is altered in TNF-Rp55-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2006;47(11):5057-5065.
10. Majka S, McGuire PG, Das A. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. Invest Ophthalmol Vis Sci. 2002;43(1): 260-266.
11. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina. 2007; 27(4):399-413.
12. Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine. 2006;33(4):231-237.
13. Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNFalpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005; 89(5):533-536.
14. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha Agents. Ann N Y Acad Sci. 2005;1051:559-569.
15. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242-251.
16. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001;57(10):1885-1888.
17. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098-1104.
18. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46(10):2565-2570.
19. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48(2):319-324.
20. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98(6):1315-1324.
21. Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Int Med. 2003;139(3):238-239.
22. ten Tusscher MP, Jacobs PJ, Busch MJ, de Graaf L, Diemont WL. Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ. 2003;326(7389):579.
23. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-2285.
24. Giansanti F, Ramazzotti M, Vannozzi L, et al. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci. 2008;49(3):1151-1156.
25. Theodossiadis PG, Liarakos VS, Sfikakis PP, et al. Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol. 2009;247(2):273-281.
26. Morrison VL, Koh HJ, Cheng L, Bessho K, Davidson MC, Freeman WR. Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. Retina. 2006;26(3):339-344.
27. Snowden JM, Swann DA. Vitreous structure, V: the morphology and thermal stability of vitreous collagen fibers and comparison to articular cartilage (type II) collagen. Invest Ophthalmol Vis Sci. 1980;19(6):610-618.
28. Mordenti J, Thomsen K, Licko V, et al. Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol Sci. 1999;52(1):101-106.
29. Kim H, Csaky KG, Chan CC, et al. The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res. 2006;82:760-766.
30. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007; 114(5):855-859.
31. Araie M, Maurice DM. The loss of fluorescein, fluorescein glucuronide and fluorescein isothiocyanate dextran from the vitreous by the anterior and retinal pathways. Exp Eye Res. 1991;52:27-39.
32. Maurice DM. Protein dynamics in the eye studied with labelled proteins. Am J Ophthalmol. 1959;47:361-367.
33. Heidushka P, Fietz H, Hofmeister S et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007;48:2814-2823.
34. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26:262-269.
35. 125Ilabeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27(5):536-544.
36. Sebag J. Molecular biology of pharmacologic vitreolysis. Trans Am Ophthalmol Soc. 2005;103:473-494.